Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Werewolf Therapeutics Inc. Common Stock
HOWL | US
0.92
USD0.00
0.23%
HOWL | US
About Werewolf Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
0.92
Open
0.92
High
0.94
Low
0.88
Werewolf Therapeutics Inc. a biopharmaceutical company develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company through its proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124 a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330 a conditionally activated Interleukin-12 INDUKINE molecule which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898 a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712 an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics Inc. was incorporated in 2017 and is headquartered in Watertown Massachusetts.
View LessHOWL | US
Risk
100.0
Sharpe
0.25
Luna's Score
37/100
Recommendation
Sell
Luna says (HOWL | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
111.1%1 month
100.0%3 months
95.0%6 months
105.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.86
Debt to equity
0.35
Debt to assets
0.24
Ent. to EBITDA
0.57
Ent. to rev.
0.67
PEG
-
Other Fundamentals
EBITDA
-56.51M
MarketCap
40.19M
MarketCap(USD)
40.19M
Div. yield
-
Op. margin
-1.66K
Erngs. growth
-
Rev. growth
-85.90
Ret. on equity
-48.27
Short ratio
7.94
Short perc.
4.06
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.30
Range1M
0.39
Range3M
0.61
Volumes: Market Activity
Rel. volume
0.28
Price X volume
80.60K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.57 | - | Par |
| Ent. to Revenue | 0.67 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.86 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 94.99 | - | Riskier |
| Debt to Equity | 0.35 | -1.23 | Expensive |
| Debt to Assets | 0.24 | 0.25 | Par |
| Market Cap | 40.19M | - | Emerging |
